Join Growin Stock Community!

邦特4107.TW Overview

TW StockBiotech. & Medical
(No presentation for 4107)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

邦特（4107）Overall Performance

邦特（4107）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

邦特（4107） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

邦特（4107）Key Information

邦特（4107）Profile

Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It also offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage catheter sets, introducer sets, connecting tubes, drainage bags, and radiopaque dilators; urology products comprising ureteral stent sets and urine collection bags; and IV administration products, such as PVC IV infusion bags, PVC bags, and twist-off ports. In addition, the company provides respiratory care products, such as closed suction catheters and endotracheal tubes; vascular access products comprising angiographic catheters, PTA balloon dilatation catheters, sheath introducers, guidewires, high pressure connecting tubes, PTCA balloon dilatation catheter-rapid exchange products, manifolds, and Y connectors; and medical components, including dialyzer connectors and caps, recirculating connectors with cap, rotating luer lock connectors, pump and T connectors, injection sites, female luers, luer lock and chamber caps, drip chambers, filters, clamps, pressure pillows, safeline HDF components, chamber assembly, and transducer protectors, as well as medical masks. Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.

邦特（4107）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
16.22
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
44.14%
Net Margin
24.99%
Revenue Growth (YoY)
0.31%
Profit Growth (YoY)
0.65%
3-Year Revenue Growth
2.20%
3-Year Profit Growth
2.93%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
16.22
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
44.14%
Net Margin
24.99%
Revenue Growth (YoY)
0.31%
Profit Growth (YoY)
0.65%
3-Year Revenue Growth
2.20%
3-Year Profit Growth
2.93%
default symbol

4107

邦特

122.00D

-1.64%

(-0.02)

  • When is 4107's latest earnings report released?

    The most recent financial report for 邦特 (4107) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4107's short-term business performance and financial health. For the latest updates on 4107's earnings releases, visit this page regularly.

  • Where does 4107 fall in the P/E River chart?

    According to historical valuation range analysis, 邦特 (4107)'s current price-to-earnings (P/E) ratio is 12.59, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 4107?

    According to the latest financial report, 邦特 (4107) reported an Operating Profit of 168.42M with an Operating Margin of 32.43% this period, representing a decline of 10.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4107's revenue growth?

    In the latest financial report, 邦特 (4107) announced revenue of 519.26M, with a Year-Over-Year growth rate of -6.15%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4107 have?

    At the end of the period, 邦特 (4107) held Total Cash and Cash Equivalents of 1B, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4107 go with three margins increasing?

    In the latest report, 邦特 (4107) achieved the “three margins increasing” benchmark, with a gross margin of 45.27%%, operating margin of 32.43%%, and net margin of 26.31%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4107's profit trajectory and future growth potential.

  • Is 4107's EPS continuing to grow?

    According to the past four quarterly reports, 邦特 (4107)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.97. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4107?

    邦特 (4107)'s Free Cash Flow (FCF) for the period is 41.52M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.56% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.